Switch theme
Sign up to access all valuation multiples
MEDCAMP SA is engaged in redevelopment investments. The company provides clients with the quality of development projects prepared for implementation based on revitalized real estates. It also engaged in the acquisition, management, redevelopment and upgrade, as well as rental of commercial properties, including office areas and warehouses.
1998
n/a
Last FY Revenue n/a
Last FY EBITDA $0.2M
$5.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, MEDCAMP achieved revenue of n/a and an EBITDA of $0.2M.
MEDCAMP expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MEDCAMP valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | -$0K | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | $0.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$0.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | $0.3M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | $0.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MEDCAMP's stock price is PLN 1 (or $0).
MEDCAMP has current market cap of PLN 24.6M (or $6.5M), and EV of PLN 21.8M (or $5.8M).
See MEDCAMP trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8M | $6.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MEDCAMP has market cap of $6.5M and EV of $5.8M.
MEDCAMP's trades at n/a EV/Revenue multiple, and 26.5x EV/EBITDA.
Equity research analysts estimate MEDCAMP's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MEDCAMP's P/E ratio is not available.
See valuation multiples for MEDCAMP and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5M | XXX | $6.5M | XXX | XXX | XXX |
| EV (current) | $5.8M | XXX | $5.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 26.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -75.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 20.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -71.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMEDCAMP's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
MEDCAMP's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MEDCAMP's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MEDCAMP and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Aldar Properties | XXX | XXX | XXX | XXX | XXX | XXX |
| CTP | XXX | XXX | XXX | XXX | XXX | XXX |
| Royal Heijmans | XXX | XXX | XXX | XXX | XXX | XXX |
| New Amsterdam Invest | XXX | XXX | XXX | XXX | XXX | XXX |
| DigiCo REIT | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MEDCAMP acquired XXX companies to date.
Last acquisition by MEDCAMP was XXXXXXXX, XXXXX XXXXX XXXXXX . MEDCAMP acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MEDCAMP founded? | MEDCAMP was founded in 1998. |
| Where is MEDCAMP headquartered? | MEDCAMP is headquartered in Poland. |
| Is MEDCAMP publicy listed? | Yes, MEDCAMP is a public company listed on WAR. |
| What is the stock symbol of MEDCAMP? | MEDCAMP trades under MDP ticker. |
| When did MEDCAMP go public? | MEDCAMP went public in 2007. |
| Who are competitors of MEDCAMP? | Similar companies to MEDCAMP include e.g. Aldar Properties, CTP, Royal Heijmans, New Amsterdam Invest. |
| What is the current market cap of MEDCAMP? | MEDCAMP's current market cap is $6.5M |
| Is MEDCAMP profitable? | Yes, MEDCAMP is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
